Single-center, double-blind, placebo-controlled clinical trial with two arms (product and placebo) to analyze the safety of beta-alanine consumption in active people.
After recruitment, subjects will be randomized and assigned to one of the two arms of the study: beta-alanine group or control group (placebo). Subjects must be active people, and will take a dose of 15 g per day of the product for 4 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
20
The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
Catholic University of Murcia
Murcia, Spain
Liver safety variables
It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)
Time frame: Change in hepatic safety after 8 weeks of consumption
Paresthesia test
Visual analogue scale (1-10)
Time frame: Change after 8 weeks of consumption
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.